主要原著論文 自家がんワクチンに紹介記事・論文を一覧でご紹介しています。

無料相談・お問い合わせ 029-828-5591 日曜・祝日を除き9:00～17:30

WEBで資料請求・ご相談

資料請求・ご相談

サイト内検索

English

ご相談は無料です。
お気軽にお問い合わせください。

029-828-5591029-828-5591

日曜・祝日を除き 9:00～17:30

WEBで資料請求・ご相談

お問い合わせ方法・資料ダウンロード

臨床試験成績

会社情報

紹介記事・論文

主要原著論文

46

2024.10.07

Fukuda K, Ohno T. Successful monotherapy with autologous formalin-fixed tumor vaccine for a Stage IV uterine cancer patient who rejected rational chemotherapy and immune checkpoint inhibitor treatment. Clin Case Rep. 2023 Jun 8;11(6):e7513. doi: 10.1002/ccr3.7513. 

45

2023.02.08

Muragaki Y, Ishikawa E, Maruyama T, Nitta M, Saito T, Ikuta S, Komori T, Kawamata T, Yamamoto T, Tsuboi K, Matsumura A, Nakamura H, Kuroda J, Abe T, Momii Y, Saito R, Tominaga T, Tabei Y, Suzuki I, Arakawa Y, Miyamoto S, Matsutani M, Karasawa K, Nakazato Y, Maebayashi K, Hashimoto K, Ohno T. A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas. J Neurosurg. 2023 Jan 20:1-11. doi: 10.3171/2022.12.JNS221221.

44

2020.04.04

Miyazaki T, Ishikawa E, Matsuda M, Sugii N, Kohzuki H, Akutsu H, Sakamoto N, Takano S, Matsumura A. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol. 2020; 37(2):41-49.

43

2018.01.22

Kuranishi F, Imaoka Y, Sumi Y, Uemae Y, Yasuda-Kurihara H, Ishihara T, Miyazaki T, Ohno T. Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine. Int J Breast Cancer, 2018;article ID 4879406, 11 pages.

42

2018.01.08

Imaoka Y, Kuranishi F, Miyazaki T, Yasuda-Kurihara H, Ohno T. Long-lasting complete response status of advanced stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine: Two case reports. World Journal of Surgical Oncology, 2017;15:170.

41

2017.12.28

Miyoshi T, Kashiwabara T, Asahi A, Kataoka T, Maruyama T, Okada R, Uemae Y, Ohno T. Complete remission of chemo-refractory multiple-metastatic upper tract urothelial carcinoma by autologous formalin-fixed tumor vaccine. Clin Case Reports, 2017;5:1780–1784.

40

2016.06.13

Miyoshi T, Kataoka T, Asahi A, Maruyama T, Okada R, Uemae Y, Ohno T. A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody. Clin Case Reports, 2016; 4(7): 687–691.

39

2015.10.11

Chen JT, Ohno T. Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel–carboplatin therapy responded to autologous formalin-fixed tumor vaccine. Clinical Case Reports, Article first published online: 2 SEP 2015 DOI: 10.1002/ccr3.353

38

2015.08.19

Kawashima I, Kawashima Y, Matsuoka Y, Fujise K, Sakai H, Takahashi M, Yoshikawa T, Nakatsura T, Ishihara T, Ohno T. Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3. Clin Case Rep. 2015 Jun;3(6):444-7. doi: 10.1002/ccr3.279. Epub 2015 Apr 17.

37

2014.07.04

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A. : Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

36

2013.06.04

Fumito Kuranishi and Tadao Ohno: Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report. World Journal of Surgical Oncology 2013, 11:127. Published online 2013 June 4. doi: 10.1186/1477-7819-11-127

35

2012.12.24

Yoshihiro Muragaki, Takashi Maruyama, Hiroshi Iseki, Masahiko Tanaka, Chie Shinohara, Kintomo Takakura, Koji Tsuboi, Tetsuya Yamamoto, Akira Matsumura, Masao Matsutani, Katsuyuki Karasawa, Katsunori Shimada, Naohito Yamaguchi, Yoichi Nakazato, Keiki Sato, Yoji Uemae, Tadao Ohno, and Tomokatsu Hori: Erratum of no. 32: Phase I / IIa Trial of Autologous Formalin-fixed Tumor Vaccine Concomitant with Fractionated Radiotherapy for Initially-Diagnosed Glioblastoma. J. NeuroSurgery, 2013 (e-pub ahead, 2012.12)

34

2012.07.09

Toshio Inui and Tadao Ohno: Autologous formalin-fixed tumor vaccine suppressed re-recurrence of HCV-related hepatocellular carcinoma following 29 unsuccessful treatments with extensive conventional therapy: A case report. World Journal of Surgical Oncology 2012, 10：144.

33

2011.08.24

Todoroki T, Kondo T, Sugahara S, Morishita Y, Mori K, Ohno T. : Long-term survivor of relapsed MFH on the thigh treated with autologous formalin-fixed tumor vaccine (AFTV) combined with limb-sparing surgery and radiotherapy.World J Surg Oncol. 2011 Aug 24;9:96. doi: 10.1186/1477-7819-9-96.

32

2011.08.11

Muragaki Y, Maruyama T, Iseki H, Tanaka M, Shinohara C, Takakura K, Tsuboi K, Yamamoto T, Matsumura A, Matsutani M, Karasawa K, Shimada K, Yamaguchi N, Nakazato Y, Sato K, Uemae Y, Ohno T, Okada Y, Hori T. : Phase I / IIa Trial of Autologous Formalin-fixed Tumor Vaccine Concomitant with Fractionated Radiotherapy for Initially-Diagnosed Glioblastoma.J Neurosurg. 2011 Aug;115(2):248-55. doi: 10.3171/2011.4.JNS10377. Epub 2011 May 13.

31

2011.04.25

Sakamoto N, Ishikawa E, Yamamoto T, Satomi K, Nakai K, Sato M, Enomoto T, Morishita Y, Takano S, Ohno T, Tsuboi K, Matsumura A. : Pathological Changes After Autologous Formalin-Fixed Tumor Vaccine Therapy Combined With Temozolomide for Glioblastoma -Three Case Reports-Neurol Med Chir (Tokyo). 2011;51(4):319-25.

30

2007.12.31

Harada H , Goto Y , Ohno T , Suzu S , Okada S . Proliferative activation up-regulates expression of CD4 and HIV-1 co-receptors on NK cells and induces their infection with HIV-1. Eur. J. Immunol., (2007), 37, 2184-2155.

29

2007.05.22

Ishikawa, Eiichi; Tsuboi, Koji; Yamamoto, Tetsuya; Muroi, Ai; Enomoto, Takao; Takano, Shingo; Matsumura, Akira; Ohno, Tadao: Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci., 98(8):1226-1233, 2007

28

2006.01.07

Tsurushima H, Yoshii Y, Leong KW, Ohno T.: Targeted tumor cell death induced by autologous tumor-Specific T lymphocyte recognition of wild-type p53-derived peptides. J Neurooncol. 2005 Jul 30; [Epub ahead of print]

27

2005.02.26

Ghosh, M., Koike, N., Tsunoda, S., Hirano, T., Kaul, S., Kashiwagi, H., Kawamoto, T., Ohkohchi, N., Saijo, K., Ohno, T., Miwa, M., and Todoroki, T.: Characterization and genetic analysis in the newly established human bile duct cancer cell lines. Int. J.Int J Oncol. 2005 Feb;26(2):449-56.

26

2004.12.11

Kawai K, Saijo K, Oikawa T, Ohno T, Akaza H.: Enhancement of T cell proliferative response against autologous cancer cells of a metasatic renal cell carcinoma patient after unexplained regression. Int J Urol. Dec;11(12):1130-2, 2004.

25

2004.08.01

Ishikawa, E., Tsuboi, K., Saijo, K., Takano, S., and Ohno, T.: X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions. Int. J. Radiation Oncology Biol. Phys. 59: 1505-1512, 2004

24

2004.07.03

Kushida, S., Peng, B. G., Uchimura, E., Kuang, M., Huang, L., Miwa, M., and Ohno, T.: A tumor vaccine of fixed tumor fragments in a controlled-release vehicle with cytokines for therapy of hepatoma in mice. Digestive and Liver Disease, 36: 478-485, 2004.

23

2004.06.05

Ishikawa, E., Tsuboi, K., Saijo, K.,Harada, H., Takano, S., Nose, T., Ohno, T.: Autologous Natural Killer Cell Therapy for Human Recurrent Malignat Glioma. Anticancer Research. 24: 1861-1872, 2004.

22

2004.05.24

Mila Ghosh, Naoto Koike, Go Yanagimoto, Shin-ichi Tsunoda, Sunil Kaul, Takashi Hirano, Fabian Emura, Hironobu Kashiwagi, Toru Kawamoto, Nobuhiro Ohkohchi, Kaoru Saijo, Tadao Ohno, Masanao Miwa, and Takeshi Todoroki*: Establishment and characterization of　unique human gallbladder cancer cell lines.Int J Oncol. 2004 May;24(5):1189-96.

21

2004.05.06

Harada, H., Watanabe, S., Saijo, K., Ishiwata, I., and Ohno, T.: A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp. Hematol. 32: 614-621, 2004.

20

2004.05.01

Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW, Ohno T: Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma.Clin Cancer Res. 2004 Mar 1;10(5):1574-9.

19

2004.03.01

Harada, H., Saijo, K., Ishiwata, I., and Ohno, T.: A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay. Human Cell, 17: 43-48, 2004.

18

2004.01.09

Eiichi Ishikawa , Koji Tsuboi , Shingo Takano , Eiji Uchimura , Tadao Nose, and Tadao Ohno*: Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of an intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracr.Cancer Sci. 2004 Jan;95(1):98-103.

17

2003.11.23

Fabian Emura, Hiroshi Kamma, Mila Ghosh, Naoto Koike, Toru Kawamoto, Kaoru Saijo, Tadao Ohno, Nobuhiro Ohkohchi, and Takeshi Todoroki*: Establishment and characterization of novel xenograft models of human biliary tract carcinomas. Int J Oncol. 2003 Nov;23(5):1293-300.

16

2003.08.15

Koji Tsuboi, Kaoru Saijo, Eiichi Ishikawa, Hideo Tsurushima, Shingo Takano, Yukio Morishita and Tadao Ohno: Effects of Local Injection of ex Vivo Expanded Autologous Tumor-specific T Lymphocytes in Cases with Recurrent Malignant Gliomas. Clin Cancer Res 9:3294-3302, 2003.

15

2002.04.06

Peng, B. G., Liu, S. Q., Kuang, M., He, Q., Totsuka, S., Huang, L., Huang, J., Lu, M-D., Liang, L-J., Leong, K. W., and Ohno, T.: Autologous fixed tumor vaccine: A formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma.Jpn J Cancer Res. 2002 Apr;93(4):363-8.

14

2002.03.09

Harada, H., Saijo, K., Watanabe, S., Tsuboi, K., Nose, T., Ishiwata, I., Ohno, T.*: Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn. J. Cancer Res. 93: 313-9, 2002.

13

2001.06.03

Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A., Dirks, W. G., Packer, P., Toji, L. H., Ohno, T., Tanabe, H., Arlett, C. F., Kelland, L. R., Harrison, M., Virmani, A., Ward, T. H., Ayres, K. L., Debenham, P. G.: Short tandem repeat profilingprovides an international reference standard for human cell lines.Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7. Epub 2001 Jun 19.

12

2000.06.01

Kim, C. H., Todoroki, T., Matsumura, M., and Ohno, T.: Eligibility of antigenic-peptide pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes for cancer patients with elevated serum CEA levels. J. Cancer Res. Clin.J Cancer Res Clin Oncol. 2000 Jul;126(7):383-90.

11

1999.05.09

Tsurushima, H., Liu, S. Q., Tuboi, K., Matsumura, A., Yoshii, Y., Nose, T., Saijo, K. and Ohno, T.*: Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn. J. Cancer Res.., 9, 536-545, 1999.

10

1999.05.05

Saijo Y, Hong X, Tanaka M, Tazawa R, Liu SQ, Saijo K, Ohno T, Koike K, Ohkuda K, Satoh K, Nukiwa T. : Autologous high-killing cytotoxic T lymphocytes against human lung cancer are induced using interleukin (IL)-1beta, IL-2, IL-4, and IL-6: possible involvement of dendritic cells.Clin Cancer Res. 1999 May;5(5):1203-9.

9

1998.11.08

Liu, S. Q., Kawai, K., Shiraiwa, H., Hayashi, H. Akaza, H., Hashizaki, K., Shiba, R., Saijo, K., Ohno, T.: High rate of induction of human autologous cytotoxic T lymphocytes against renal carcinoma cells cultured with an interleukin cocktail. Jpn. J. Can.Jpn J Cancer Res. 1998 Nov;89(11):1195-201.

8

1998.10.19

Kohyama, M., Saijo, K., Hayashida, M., Yasugi, T., Kurimoto, M., and Ohno, T.*: Direct activation of human CD8+ cytotoxic T lymphocytes by interelukin-18. Jpn. J. Cancer Res., 89: 1041-1046, 1998.

7

1998.10.04

Kim, C., Matsumura, M., Saijo, K., Ohno, T.*: In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol. Immunother., 47: 90-96, 1998.

6

1998.03.26

Horiuchi, K., Tsurushima, H., Kim, B. S., Liu, S. Q., Saijo, K., Saijo, Y., Nukiwa, T., Nomura, N., Matsumura, M., Ohno, T.*: Expansion of human autologous cytotoxic T lymphocytes on fixed target tumor cells. Cytotechnology. 1998 Mar;26(2):119-24. doi: 10.1023/A:1007903614475.

5

1996.12.02

Liu, S. Q., Shiraiwa, H., Kawai, K., Hayashi, H., Akaza, H., Kim, B. S., Oki, A., Nishida, M., Kubo, T., Hashizaki, K., Saijo, K. and Ohno, T.*: Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nature Medicine, 2: 1283-1283, 1996.

4

1996.02.08

Tsurushima, H., Liu, S. Q., Tsuboi, K., Yoshii, Y., Nose, T. and Ohno, T.*: Induction of human autologous cytotoxic T lymphocytes on minced tissues of the brain tumor, glioblastoma multiforme. J. Neurosurgery, 84, 258-263, 1996.

3

1995.03.01

Liu, S. Q., Saijo, K., Todoroki, T., and Ohno, T.* : Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Medicine, 1, 267-271, 1995.

2

1994.06.08

Liu, S. Q., Shiba, R. Kim, B. S., Saijo, K. and Ohno, T.* : Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells. Cancer Immunol. Immunother., 39, 279-285, 1994.

1

1992.04.24

Kawai, K., Sasaki, T., Saijo-Kurita, K., Akaza, H., Koiso, K., and Ohno, T.: Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase assay. Cancer Immunol Immunother. 1992;35(4):225-9.

注：弊社は病院やクリニックではなくバイオ企業であるため、症例報告や論文内容のWeb掲載は許容されています。

一般の方へ

受診の流れ

がん組織の確保

診療価格

がん治療の担当医も納得の有効症例の数々

有効症例ライブラリー

セルメディシンニュース購読登録（無料）

資料請求（無料）

医療関係の方へ

がん治療の担当医も納得の有効症例の数々

臨床試験成績

学術論文

提携をご希望の臨床医の先生方へ

ピックアップ

会社情報

社長略歴

採用情報

よくあるご質問（Q&A）

用語集

トピックス一覧

お知らせ一覧

ご相談は無料です。
お気軽にお問い合わせください。

029-828-5591 029-828-5591

日曜・祝日を除き 9:00～17:30

WEBで資料請求・ご相談

お問い合わせ方法・資料ダウンロード